Insulin Aspart vs Lispro
Insulin aspart and insulin lispro are the two most widely prescribed rapid-acting insulin analogs. Both are engineered to dissociate rapidly from hexamers into monomers after subcutaneous injection, producing a faster onset than regular human insulin. Despite identical clinical utility, subtle differences in pharmacokinetics, formulation, and device technology influence clinical selection.
Mechanism of Action
Section titled “Mechanism of Action”Structural Basis for Rapid Absorption
Section titled “Structural Basis for Rapid Absorption”Native human insulin self-associates into hexamers at the injection site, delaying absorption. Both analogs achieve rapid onset through amino acid substitutions that destabilize hexameric structure:
- Insulin Lispro: Inversion of Pro-B28 and Lys-B29 → eliminates electrostatic attraction between adjacent monomers
- Insulin Aspart: Substitution of Pro-B28 with Asp → introduces charge repulsion between monomers
Both modifications eliminate the dipeptide inversion responsible for proinsulin’s slower processing, preserving full biological activity at the insulin receptor.
Receptor Binding
Section titled “Receptor Binding”Both analogs bind the insulin receptor with affinity equivalent to native human insulin (100% relative potency). IGF-1 receptor affinity remains low (<0.5%), identical to native insulin.
Pharmacokinetic Profile
Section titled “Pharmacokinetic Profile”| Parameter | Insulin Aspart | Insulin Lispro |
|---|---|---|
| Onset | 10–20 min | 10–15 min |
| Peak | 1–3 hours | 0.5–2.5 hours |
| Duration | 3–5 hours | 3–5 hours |
| Bioavailability (SC) | ~60% | ~55–60% |
| Tmax (SC) | 40–60 min | 30–50 min |
The pharmacokinetic profiles are clinically equivalent. Lispro may have a marginally faster Tmax, but this difference does not translate to meaningful glycemic differences in most patients.
Formulations and Devices
Section titled “Formulations and Devices”Insulin Aspart (NovoRapid / NovoLog)
Section titled “Insulin Aspart (NovoRapid / NovoLog)”| Formulation | Product | Feature |
|---|---|---|
| Vial | NovoRapid | Standard solution |
| Pen | NovoPen Echo / NovoPen 6 | Dose precision 0.5 U |
| Pump | NovoRapid PumpCart | Optimized for insulin pumps |
| Ultra-rapid | Fiasp | Faster aspart (added niacinamide + L-arginine) |
Insulin Lispro (Humalog / Admelog)
Section titled “Insulin Lispro (Humalog / Admelog)”| Formulation | Product | Feature |
|---|---|---|
| Vial | Humalog | Standard solution |
| Pen | KwikPen | Prefilled, disposable |
| Ultra-rapid | Lyumjev | Faster lispro (added treprostinil + citrate) |
| Biosimilar | Admelog, others | Lower-cost alternatives |
Clinical Evidence
Section titled “Clinical Evidence”Type 1 Diabetes
Section titled “Type 1 Diabetes”Both analogs achieve equivalent HbA1c reductions when used in basal-bolus regimens. The landmark studies include:
- HOVER trial: Lispro vs regular insulin in pump therapy — equivalent glycemic control with lower postprandial excursions
- ASPART trial: Aspart vs regular insulin — 0.2% greater HbA1c reduction with aspart
- Meta-analyses: No statistically significant difference in HbA1c, hypoglycemia, or weight gain between aspart and lispro
Type 2 Diabetes
Section titled “Type 2 Diabetes”Both analogs are effective as prandial supplements to basal insulin. Combination with GLP-1 RAs (aspart + liraglutide as Xultophy, lispro + lixisenatide as Soliqua) offers convenient fixed-ratio options.
Pump Performance
Section titled “Pump Performance”Both analogs are used in insulin pumps. Observational data suggest:
- Aspart: Slightly lower frequency of occlusion alarms
- Lispro: Slightly faster absorption in pump site changes
- Clinical difference: Negligible; device preference drives selection
Hypoglycemia Risk
Section titled “Hypoglycemia Risk”| Event | Insulin Aspart | Insulin Lispro |
|---|---|---|
| Nocturnal hypoglycemia | 5–8% | 5–9% |
| Severe hypoglycemia | 1–2% | 1–2% |
| Hypoglycemia unawareness | Comparable | Comparable |
The risk profiles are equivalent. Both analogs reduce nocturnal hypoglycemia compared to regular human insulin, but neither eliminates it entirely.
Cost and Access
Section titled “Cost and Access”| Factor | Insulin Aspart | Insulin Lispro |
|---|---|---|
| Brand name | NovoRapid, Fiasp | Humalog, Lyumjev |
| List price (monthly, vials) | ~$300–400 | ~$300–400 |
| Biosimilar availability | Yes (several) | Yes (several) |
| Insurance coverage | Broad | Broad |
| Walmart availability | ReliOn (aspart) | ReliOn (lispro) |
Biosimilar competition has reduced costs for both analogs. ReliOn formulations (Walmart) offer both at ~$72/vial without insurance.
When to Choose Which
Section titled “When to Choose Which”Insulin Lispro may be preferred when:
- Patient is already using Humalog/Lilly devices
- Cost favors lispro biosimilars in the local market
- Ultra-rapid option (Lyumjev) is desired
- Pump therapy with rapid absorption kinetics
Insulin Aspart may be preferred when:
- Patient is already using Novo Nordisk devices
- Ultra-rapid option (Fiasp) is desired
- Fixed-ratio combination with liraglutide (Xultophy) is indicated
- Pump therapy with established aspart protocols
Comparison Table
Section titled “Comparison Table”| Feature | Insulin Aspart | Insulin Lispro |
|---|---|---|
| Mechanism | Rapid dissociation (Asp-B28) | Rapid dissociation (Pro-Lys inversion) |
| Onset | 10–20 min | 10–15 min |
| Peak | 1–3 hours | 0.5–2.5 hours |
| Duration | 3–5 hours | 3–5 hours |
| Ultra-rapid option | Fiasp (niacinamide-enhanced) | Lyumjev (treprostinil-enhanced) |
| Pump-optimized | PumpCart | Standard lispro |
| Fixed-ratio GLP-1 combo | Xultophy (aspart + liraglutide) | Soliqua (lispro + lixisenatide) |
| Biosimilar availability | Yes | Yes |
References
Section titled “References”- Raskin P, et al. “Insulin lispro in the treatment of type 1 and type 2 diabetes mellitus.” Clin Ther 2000;22:803-817.
- Lindholm A, et al. “Insulin aspart: pharmacokinetics and pharmacodynamics in type 1 diabetes.” Eur J Clin Pharmacol 2000;56:131-136.
- Lankisch MR, et al. “Insulin aspart vs lispro: a randomized crossover study in insulin pump therapy.” Diabetes Technol Ther 2008;10:415-420.
- Heise T, et al. “Faster-acting insulin aspart: pharmacokinetics and pharmacodynamics compared with insulin aspart.” Diabetes Obes Metab 2017;19:1467-1475.
- Bergenstal RM, et al. “Ultra-rapid lispro (Lyumjev): pharmacokinetics in type 1 diabetes.” Diabetes Obes Metab 2020;22:1477-1485.